Researchers from Pfizer Inc. presented preclinical data for the melanocortin MC4 receptor (MC4R) antagonist PF-07258669, being developed for the treatment of anorexia nervosa.
Circadian rhythm disorders are associated with psychiatric disorders including depression, bipolar disease and schizophrenia. To target casein kinase I isoform delta (CKI-delta), Janssen Pharmaceutica NV scientists sought potent, selective, brain-penetrant CKI-delta inhibitors which can be dosed daily and orally.
Arcturus Therapeutics Inc. has obtained an award for up to US$63.2 million from the Biomedical Advanced Research and Development Authority (BARDA) to expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform.
MC2 Therapeutics A/S has discovered that carbamylation of proteins, peptides and amino acids in the skin, caused by isocyanate, may be the root cause of several urea-associated skin diseases, such as chronic kidney disease-associated pruritus (CKD-aP, or uremic pruritus) and genital lichen sclerosus.
Mas-related G-protein coupled receptor X2 (MRGPRX2) is expressed particularly on mast cells and its activation leads to the mast cell degranulation with release of inflammatory mediators.
Laverock Therapeutics Ltd. (formerly Skylark Therapeutics) recently completed a seed funding round to support its development of a unique gene silencing platform for the creation of programmable, allogeneic cell therapies.
Eikonizo Therapeutics Inc. has identified histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer and neurological disorders, among others.
Black Diamond Therapeutics Inc. has patented quinoxaline derivatives acting as fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer.
RSS
